Maridebart Cafraglutide
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SW
Amgen · Phase 3 · Recruiting · Enrollment 300
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| MariTide Arm 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| MariTide Arm 2 | Obesity or overweight | n/r | n/r | n/r | n/r |